Home Cart Sign in  
Chemical Structure| 943962-47-8 Chemical Structure| 943962-47-8

Structure of BMS-303141
CAS No.: 943962-47-8

Chemical Structure| 943962-47-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-303141 is a potent ATPcitrate lyase (ACL) inhibitor with IC50 of 0.13 μM (human recombinant ACL).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-303141

CAS No. :943962-47-8
Formula : C19H15Cl2NO4S
M.W : 424.30
SMILES Code : O=S(C1=CC(Cl)=CC(Cl)=C1O)(NC2=CC(C3=CC=CC=C3)=CC=C2OC)=O
MDL No. :MFCD25976797
InChI Key :SIIPNDKXZOTLEA-UHFFFAOYSA-N
Pubchem ID :16747776

Safety of BMS-303141

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 10 μmol/L or 20 μmol/L Evaluate the effect of SR9009 on BMAL1 mRNA expression PMC7875901

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BLKS/J mice Db/db mouse model Oral 50 mg/kg Once daily for 30 days BMS-303141 administration could decrease the levels of serum lipid and renal lipogenic enzymes acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), HMG-CoA reductase (HMGCR), and diminish renal ELA in db/db mice. In addition, we found that reducing ELA improved renal injuries, inflammation, and tubulointerstitial fibrosis. PMC9771989
BALB/c nude mice HepG2 xenograft model Gavage 5 mg/kg/d Once daily for 8 days Combined treatment with sorafenib reduced HepG2 tumour volume and weight PMC7875901
Mice Db/db mice Oral 50 mg/kg Once daily for 30 days To evaluate the therapeutic effect of ACL inhibitors on obesity-related nephropathy, the results showed that BMS-303141 could reduce ectopic lipid accumulation and inflammation in the kidney. PMC9771989

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.57mL

4.71mL

2.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories